Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT03259555Phase 3Completed
A Phase 3 trial of brexpiprazole orally disintegrating tablet in bipolar I disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Sep 2017; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT03259555.